Silverman targets Alzheimer's, ALS with new drug
January 8, 2026
An experimental drug developed in the lab of Rick Silverman has demonstrated further promise as an early intervention for Alzheimer’s disease. Northwestern University researchers aren’t targeting a specific condition. Instead, they're focused on a problem: the buildup of toxic proteins in the neurons that block normal function and eventually cause symptoms.